HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer
- PMID: 25389328
- DOI: 10.1309/AJCPIRL4GUVGK3YX
HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer
Abstract
Objectives: Heterogeneity of HER2 gene amplification is found in a subset of breast cancers. We investigated the impact of HER2 heterogeneity on trastuzumab responses and clinical outcomes in 112 patients with HER2-positive metastatic breast cancer.
Methods: Regional and genetic heterogeneity of HER2 gene amplification was determined in three different areas of each tumor by immunohistochemistry and silver in situ hybridization. We also assessed the overall levels of HER2 amplification and the proportion of tumor cells with a HER2/CEP17 ratio of more than 2.2 or strong and complete membranous (3+) expression of HER2 protein.
Results: HER2 regional and genetic heterogeneity based on the HER2/CEP17 ratio was confirmed in 8.7% and 2.7% of cases, respectively. Poor response to trastuzumab was associated with overall low-level or equivocal amplification, HER2 regional heterogeneity by the HER2/CEP17 ratio, the HER2/CEP17 ratio of more than 2.2 in less than 80% of tumor cells, and HER2 immunohistochemical expression of 3+ in less than 75% of tumor cells. In survival analyses, low-level or equivocal HER2 amplification, HER2 regional heterogeneity based on the HER2/CEP17 ratio, and the HER2/CEP17 ratio of more than 2.2 in less than 80% of tumor cells were associated with shorter time to progression and lower overall survival in univariate and multivariate analyses.
Conclusions: These results suggest that accurate assessment of HER2 status, including HER2 heterogeneity, is important in predicting trastuzumab responses and outcomes in patients with HER2-positive metastatic breast cancer.
Keywords: Breast carcinoma; Gene amplification; HER2; Heterogeneity; Trastuzumab.
Copyright© by the American Society for Clinical Pathology.
Similar articles
-
Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.Am J Clin Pathol. 2015 Oct;144(4):570-8. doi: 10.1309/AJCP51HCGPOPWSCY. Am J Clin Pathol. 2015. PMID: 26386078
-
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.J Clin Oncol. 2013 Dec 10;31(35):4445-52. doi: 10.1200/JCO.2013.48.9070. Epub 2013 Oct 14. J Clin Oncol. 2013. PMID: 24127447
-
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.Clin Breast Cancer. 2005 Aug;6(3):240-6. doi: 10.3816/CBC.2005.n.026. Clin Breast Cancer. 2005. PMID: 16137435
-
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Mod Pathol. 2014 Jan;27(1):4-18. doi: 10.1038/modpathol.2013.103. Epub 2013 Jun 28. Mod Pathol. 2014. PMID: 23807776 Review.
-
Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.Oncol Nurs Forum. 2006 Nov 3;33(2):265-72. doi: 10.1188/06.ONF.265-272. Oncol Nurs Forum. 2006. PMID: 16518442 Review.
Cited by
-
Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy.Biomedicines. 2024 May 14;12(5):1088. doi: 10.3390/biomedicines12051088. Biomedicines. 2024. PMID: 38791050 Free PMC article. Review.
-
Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers for trastuzumab resistance of breast cancer.Breast Cancer Res Treat. 2024 Aug;207(1):187-201. doi: 10.1007/s10549-024-07355-1. Epub 2024 May 15. Breast Cancer Res Treat. 2024. PMID: 38750271
-
Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and/or EGFR.iScience. 2024 Apr 15;27(5):109750. doi: 10.1016/j.isci.2024.109750. eCollection 2024 May 17. iScience. 2024. PMID: 38711454 Free PMC article.
-
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer.NPJ Breast Cancer. 2024 Jan 2;10(1):2. doi: 10.1038/s41523-023-00605-3. NPJ Breast Cancer. 2024. PMID: 38167908 Free PMC article.
-
Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.Int J Mol Sci. 2023 Aug 14;24(16):12795. doi: 10.3390/ijms241612795. Int J Mol Sci. 2023. PMID: 37628975 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous